SCHEMBL14486374

SCHEMBL14486374

CC(C)(C)OC(=O)N1CCN(c2nc(Br)ns2)CC1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CKS1B P61024 2/20 0.44
SKP1 P63208 2/20 0.44
SKP2 Q13309 2/20 0.44
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
KCNH2 Q12809 2/20 0.43
MAP4K4 O95819 1/20 0.42
USP2 O75604 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
GBA1 P04062 1/20 0.41
GPR119 Q8TDV5 3/20 0.40
BACE1 P56817 2/20 0.40
ACHE P22303 1/20 0.40
SMARCA2 P51531 1/20 0.39
SMARCA4 P51532 1/20 0.39
PBRM1 Q86U86 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26483104 0.83 POLB (0.44) CKS1BSKP1SKP2ALDH1A1LMNA
SCHEMBL15876877 0.79 ALDH1A1 (0.44) CKS1BSKP1SKP2ALDH1A1LMNA
SCHEMBL2070545 0.78 GBA1 (0.47) CKS1BSKP1SKP2ALDH1A1LMNA
SCHEMBL25233296 0.77 STS (0.43) CKS1BSKP1SKP2ALDH1A1LMNA
SCHEMBL3768360 0.77 NPC1 (0.70) CKS1BSKP1SKP2NPC1RAB9A
SCHEMBL1199336 0.77 GPR119 (0.49) CKS1BSKP1SKP2ALDH1A1LMNA
SCHEMBL10297496 0.76 GPR119 (0.55) CKS1BSKP1SKP2ALDH1A1LMNA
SCHEMBL4850285 0.75 DPP4 (0.47) CKS1BSKP1SKP2ALDH1A1LMNA
SCHEMBL3766128 0.74 NPC1 (0.52) CKS1BSKP1SKP2NPC1RAB9A
SCHEMBL3765743 0.74 GBA1 (0.64) CKS1BSKP1SKP2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9023852-B2 1, 2, 4-thiadiazol-5-ylpiperazine derivatives useful in the treatment of neurodegenerative diseases REMYND NV (BE) 2015-05-05 US disclosed
EP-2726470-B1 1,2,4-THIADIAZOL-5-YLPIPERAZINE DERIVATIVES USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2015-04-29 EP disclosed
US-20140128404-A1 1, 2, 4-Thiadiazol-5-Ylpiperazine derivatives useful in the treatment of neurodegenerative diseases REMYND NV (BE) 2014-05-08 US disclosed
EP-2726470-A1 1, 2, 4 -THIADIAZOL- 5 -YLPIPERAZINE DERIVATIVES USEFUL IN THE TREATMENT NEURODEGENERATIVE DISEASES reMynd NV (BE) 2014-05-07 EP disclosed
CN-103619825-A 1, 2, 4-thiadiazol-5-ylpiperazine derivatives useful in the treatment neurodegenerative diseases REMYND NV 2014-03-05 CN disclosed
WO-2013004642-A1 1, 2, 4 -THIADIAZOL- 5 -YLPIPERAZINE DERIVATIVES USEFUL IN THE TREATMENT NEURODEGENERATIVE DISEASES REMYND NV (BE) 2013-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140128404-A1 1, 2, 4-Thiadiazol-5-Ylpiperazine derivatives useful in the treatment of neurodegenerative diseases MAPT, PSEN1, PSEN2 CKS1B 1508/4885SKP1 61/4885SKP2 158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.